News | November 22, 2021
Merck showcases potential for several cancers, MS and lupus
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
